CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica's lead product candidate Auxora™ has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials and been well-tolerated in over 350 critically ill patients dosed. CalciMedica has announced data for a Phase 2b trial (called CARPO – NCT04681066) in patients with acute pancreatitis (AP) and accompanying systemic inflammatory response syndrome (SIRS) and for a Phase 2 trial (called CARDEA – NCT04345614) in patients with COVID pneumonia. The Company is currently conducting a Phase 2 trial (called KOURAGE –NCT06374797) in patients with acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF).
Company Details
- Employees
- 17
- Founded
- -
- Address
- 505 Coast Blvd S,
- Industry
- Biotechnology
- Website
- https://www.calcimedica.com/
- HQ
- La Jolla, California
Calcimedica Questions
Calcimedica's website is https://www.calcimedica.com/
Calcimedica's LinkedIn profile is https://www.linkedin.com/company/calcimedica
Calcimedica has
17 employees.
View email and phone details for 17
employees at Calcimedica.
Calcimedica's industry is
Biotechnology
Calcimedica's top competitors are
Cenna Biosciences,
Atai Life Sciences,
Denovicon Therapeutics,
Sionna Therapeutics,
Bridgebio,
Third Harmonic Bio,
A28 Therapeutics,
Aspen Neuroscience, Inc.,
Crinetics Pharmaceuticals,
Portal Therapeutics.
Calcimedica's categories are Biotechnology
Calcimedica's founding year is 2007
